NCT02447432View on ClinicalTrials.gov

A Study to Compare the Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed 1-dose Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy Infants

PHASE3CompletedINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

June 11, 2015

Primary Completion Date

January 23, 2016

Study Completion Date

May 22, 2016

Conditions
Infections, Streptococcal
Interventions
BIOLOGICAL

Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (4-dose presentation)

4 doses by intramuscular injection in the right left anterolateral thigh

BIOLOGICAL

Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (1-dose presentation)

4 doses by intramuscular injection in the right anterolateral thigh

BIOLOGICAL

DTPw-HBV/Hib

3 doses by intramuscular injection in the left anterolateral thigh

Trial Locations (1)

1000

GSK Investigational Site, Dhaka

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02447432 - A Study to Compare the Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed 1-dose Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy Infants | Biotech Hunter | Biotech Hunter